Capabilities
ReiThera offers fully integrated services spanning Technology Development, Process Development, and GMP Manufacturing. From early-stage vector design to clinical-grade production, our end-to-end capabilities ensure a seamless, scalable path to market for genetic vaccines and advanced therapies.
Technology Development
Our Technology Development Unit drives innovation in viral and non-viral vector platforms. We offer custom solutions in vector engineering, plasmid design, and analytical method development—supporting seamless transitions from research to GMP. Powered by proprietary cell lines and deep molecular expertise, we turn complex challenges into high-performing, scalable technologies.
Process Development
ReiThera’s Process Development team designs and optimizes upstream and downstream workflows for scalable viral vector manufacturing. Using advanced bioreactor systems and purification strategies, we ensure high-yield, GMP-ready processes. Our data-driven approach accelerates tech transfer, reduces risk, and delivers consistent quality across development stages—from proof-of-concept to clinical scale.
GMP Manufacturing
Our GMP-certified facility enables end-to-end manufacturing of viral vectors and ATMPs under the highest quality standards. With 2,000L bioreactors, aseptic fill-finish, and flexible production suites, we support clinical and commercial supply. Segregated operations, validated processes, and full regulatory compliance ensure safety, scalability, and delivery confidence for your programs.
Quality system
At ReiThera, quality is not a function, it is embedded across every stage of development and manufacturing. Our integrated Quality System ensures that every product we support meets the highest international standards, enabling reliable delivery from early clinical phases through advanced development.
Analytics
Analytical development is a critical component of successful viral vector and advanced therapy programs. At ReiThera, Analytics is fully integrated with Process Development, Manufacturing, and Quality functions to provide the scientific understanding required to accelerate development and support regulatory success.
Proprietary platform
Innovative Technologies for Next-Generation Vaccines and Therapies
At ReiThera, we develop and manufacture advanced genetic vaccines and biotherapeutics using proprietary platform technologies designed for safety, scalability, and clinical impact. Our platforms – MVA and GRAd – support the full development lifecycle, from early design to GMP production, accelerating the path from lab to clinic.
Built for Clinical and Commercial Success
With end-to-end capabilities under one roof, ReiThera provides:
Seamless scale-up
from process development to GMP
Full control of upstream, downstream, and fill-finish operations
Manufacturing solutions tailored for early-stage studies through to market supply
Our facility
ReiThera’s GMP facility is a cutting-edge site for viral vector and biologics manufacturing. It features large-scale bioreactors, advanced cleanrooms, and aseptic filling capabilities, supporting end-to-end development and production under the highest quality standards for both clinical and research applications.